



Tel: 905-946-1066
Fax: 905-946-9524
www.bdo.ca

BDO Canada LLP
60 Columbia Way
Suite 300
Markham, Ontario L3R 0C9

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Service Newfoundland & Labrador
Office of the Superintendent of Securities, Prince Edward Island

Cardiol Therapeutics Inc.

Dear Sirs/Mesdames:

We refer to the prospectus of Cardiol Therapeutics Inc. (“the Company”) dated December 14, 2018 relating to the sale and issue of Units (the “Prospectus”).

We consent to being named and to the use in the above-mentioned Prospectus, of our report dated December 14, 2018 to the directors and shareholders of the Company on the following financial statements:

- statement of financial position as at December 31, 2017;
- statements of loss and comprehensive loss, cash flows and changes in equity for the period from incorporation on January 19, 2017 to December 31, 2017, and a summary of significant accounting policies and other explanatory information.

We report that we have read the Prospectus and all information specifically incorporated therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus as these terms are described in the CPA Canada Handbook - Assurance.

BDO Canada S.R.L./S.E.N.C.R.L./LLP

Markham, Ontario
December 14, 2018